Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | MME | P08473 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | PPARA | Q07869 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL599322 | 1.00 | FPR2 (0.57) | FPR2KMT2AMMEL3MBTL1PPARG | |
| SCHEMBL27709327 | 0.88 | ATM (0.61) | L3MBTL1ATMALDH1A1GAATHRB | |
| SCHEMBL10296148 | 0.88 | ATM (0.61) | L3MBTL1ATMALDH1A1GAATHRB | |
| SCHEMBL12386795 | 0.86 | MMP1 (0.50) | FPR2PPARGPPARAATMALDH1A1 | |
| Hydrochloric Acid SCHEMBL5934809 | 0.86 | ATM (0.60) | L3MBTL1ATMALDH1A1GAATHRB | |
| SCHEMBL476060 | 0.86 | FOLH1 (0.56) | KMT2AMMEL3MBTL1NAALAD2 | |
| SCHEMBL476061 | 0.86 | FOLH1 (0.56) | KMT2AMMEL3MBTL1NAALAD2 | |
| Hydrochloric Acid SCHEMBL5934813 | 0.86 | ATM (0.60) | L3MBTL1ATMALDH1A1GAATHRB | |
| SCHEMBL12386816 | 0.86 | MMP2 (0.58) | FPR2KMT2AL3MBTL1PPARGPPARA | |
| SCHEMBL9388989 | 0.85 | MMP1 (0.53) | FPR2ALDH1A1MMP2MMP9THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630588-B2 | Bicyclic peptide ligands specific for CD137 | BICYCLETX LIMITED (GB) | 2026-05-19 | — | — | US | claimed |
| US-20250059236-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR CD137 | BICYCLETX LIMITED (GB) | 2025-02-20 | — | — | US | claimed |
| US-20190177370-A1 | PEPTIDE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, OR PRODRUG THEREOF | TOKYO UNIVERSITY OF PHARMACY & LIFE SCIENCES (JP) | 2019-06-13 | — | — | US | claimed |
| US-6232305-B1 | ANTICANCER AGENTS; BONE DISORDERS; ANTIARTHRITIC AGENTS; RESPIRATORY SYSTEM DISORDERS | NAEJA PHARMACEUTICAL INC. (CA) | 2001-05-15 | — | — | US | claimed |
| CN-1089269-A | Novel 5-amino-4-hydroxy caproic acid derivative as therapeutical agent | CIBA GEIGY AG (CH) | 1994-07-13 | — | — | CN | claimed |
| US-12630588-B2 | Bicyclic peptide ligands specific for CD137 | BICYCLETX LIMITED (GB) | 2026-05-19 | — | — | US | disclosed |
| CN-115298194-B | VIPR2 antagonistic peptide | 一丸自然美健有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-20260124312-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EPHA2 | BICYCLETX LIMITED (GB) | 2026-05-07 | — | — | US | disclosed |
| US-20260035408-A1 | WKYMVm peptide analogues having six residues and uses thereof | RESEARCH & BUSINESS FOUND SUNGKYUNKWAN UNIV (KR) | 2026-02-05 | — | — | US | disclosed |
| US-12534498-B2 | Compounds for use as apelin receptor antagonists | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2026-01-27 | — | — | US | disclosed |
| US-20260001924-A1 | NEMO COILED COIL MIMICS AND METHODS OF USING SAME | NEW YORK UNIVERSITY (US) | 2026-01-01 | — | — | US | disclosed |
| EP-3876973-B1 | INTERLEUKIN 10 CONJUGATES AND USES THEREOF | SYNTHORX INC (US) | 2025-10-22 | — | — | EP | disclosed |
| EP-0979240-A1 | SERINE PROTEASE INHIBITORS | Akzo Nobel N.V. (NL) | 2000-02-16 | — | — | EP | disclosed |
| WO-1998050420-A1 | SERINE PROTEASE INHIBITORS | AKZO NOBEL N.V. (NL) | 1998-11-12 | — | — | WO | disclosed |
| EP-0846127-A1 | ACYLATED OLIGOPEPTIDE DERIVATIVES HAVING CELL SIGNAL INHIBITING ACTIVITY | Novartis AG (CH) | 1998-06-10 | — | — | EP | disclosed |
| WO-1997008193-A1 | ACYLATED OLIGOPEPTIDE DERIVATIVES HAVING CELL SIGNAL INHIBITING ACTIVITY | NOVARTIS AG (CH) | 1997-03-06 | — | — | WO | disclosed |
| WO-1997007131-A1 | ACYLATED OLIGOPEPTIDES CONTAINING PHOSPHOTYROSINE AS INHIBITORS OF PROTEIN TYROSINE KINASES | NOVARTIS AG (CH) | 1997-02-27 | — | — | WO | disclosed |
| CN-1112125-A | Acyloxyhexanoic acid derivatives | CIBA GEIGY AG (CH) | 1995-11-22 | — | — | CN | disclosed |
| CN-1089269-A | Novel 5-amino-4-hydroxy caproic acid derivative as therapeutical agent | CIBA GEIGY AG (CH) | 1994-07-13 | — | — | CN | disclosed |
| US-4455303-A | Renin inhibitors | THE GENERAL HOSPITAL CORPORATION (US) | 1984-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630588-B2 | Bicyclic peptide ligands specific for CD137 | PTMS, IL36G, HLA-A | FPR2 849/4885KMT2A 1335/4885MME 256/4885 |
| US-12534498-B2 | Compounds for use as apelin receptor antagonists | APLNR, NPBWR1, AP3B1 | FPR2 95/4885KMT2A 903/4885MME 78/4885 |
| US-20190177370-A1 | PEPTIDE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, OR PRODRUG THEREOF | MYOF, MSTN, VIP | FPR2 3389/4885KMT2A 1586/4885MME 124/4885 |
| US-20260124312-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EPHA2 | EPHA2, EPHB2, ERBB2 | FPR2 955/4885KMT2A 1304/4885MME 1596/4885 |
| US-20250059236-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR CD137 | CD2BP2, CD40, SDC1 | FPR2 239/4885KMT2A 4692/4885MME 696/4885 |
| US-20260001924-A1 | NEMO COILED COIL MIMICS AND METHODS OF USING SAME | DDX21, PHAX, RBX1 | FPR2 904/4885KMT2A 2849/4885MME 3554/4885 |
| US-20260035408-A1 | WKYMVm peptide analogues having six residues and uses thereof | HNMT, LTK, FPR3 | FPR2 4/4885KMT2A 1351/4885MME 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.